HIT·IQ

ASX ANNOUNCEMENT

25 JULY 2023



HITIQ PRESENTS AT BIOSHARES BIOTECH SUMMIT

Transformative, concussion management technology company, HITIQ Limited (ASX: HIQ) (HITIQ or the Company), is pleased to advise that Damian Hawes, Chief Commercial Officer of HITIQ, will be presenting at the 17th Bioshares Biotech Summit in Hobart, Tasmania, today 25 July 2023.

The Bioshares Biotech Summit's unique format brings together biotechnology companies and fund managers, stockbrokers and investment bankers active in the sector as well as retail investors who have a committed interest in biotech stocks or are looking to build their knowledge and networks in this space.

A distinguishing feature of the Summit is that companies are asked not to present a standard pitch deck, but to present on themes that provide an opportunity for investors to gain a deeper understanding on each company's business, challenges and opportunities.

Given the significant media and community interest, along with emerging evidence of a link between head impact exposure and Chronic Traumatic Encephalopathy (CTE), the Company is delighted to outline our approach as the global leader in concussion and brain health technologies in sport.

A copy of the presentation is attached.

- ENDS –

Authorised for release by the Board of Directors.


For more information, contact:

Mike Vegar
CEO & MD
HITIQ Limited
investors@hitiq.com

About HITIQ

HITIQ Limited (ASX: **HIQ**) operates in the healthcare equipment sector, providing and further developing a transformative, end-to-end concussion management technology platform. This platform aims to provide a total concussion ecosystem whereby the Company's products support the identification, monitoring and management of sport related brain injury. HITIQ's product suite utilises high-end technology that will span multiple domains – from early detection and surveillance to assessment and rehabilitation technology tools.

HITIQ is targeting a growing worldwide concussion management market including elite and recreational sport, clinical practitioners, military, research, and combat sports. The Company's first commercial partner is the Australian Football League, with current strategy initiatives expanding commercially into Rugby League, Rugby Union, Ice Hockey, Lacrosse, MMA and American Football (particularly the NCAA). The market opportunity globally represents ~500k athletes within the elite market and ~10million in the consumer market.[1]



HIT·IQ

Bioshares BioTech Summit

25th July 2023

Damien Hawes
Chief Commercial Officer

Disclaimer

This presentation has been prepared by HITIQ Limited (HIQ) and is provided for general information purposes only. No party other than HITIQ has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this presentation.

This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. HITIQ makes no warranty or representation (express or implied) as to the accuracy, reliability or completeness of the information contained in this presentation. Specifically, several matters referred to in the presentation remain under investigation and are subject to change or even elimination, depending on further research and investigation. Further, any opinions (including any forward-looking statements) expressed in this presentation are subject to change without notice. HITIQ and its directors, officers, employees, advisers and agents shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, contained in or derived from or for any omissions from this presentation, except liability under statute that cannot be excluded.

This presentation, including the information contained in this disclaimer, does not form part of any offer, invitation or recommendation in respect of shares, or an offer, invitation or recommendation to sell, or a solicitation of any offer to buy, shares in the United States, or in any other jurisdiction in which, or to any person to whom, such an offer would be illegal.

This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks, uncertainties and assumptions, many of which are outside the control of HITIQ. Actual values, results or events may be materially different to those expressed or implied in this presentation depending on a range of factors. Given these uncertainties, recipients are cautioned not to place reliance on forward-looking statements. No representation or warranty (express or implied) is made by HITIQ or any of its directors, officers, employees, advisers or agents that any forecasts, projections, intentions, expectations or plans set out in this presentation will be achieved.

Overview

1. Capital Structure
2. Supported by World-Leading Advisors
3. About
4. The Challenge
5. Global Trends and Increased Concussion Awareness
4. Product Suite
5. Global Data Collection
6. Strategies for Accelerating Adoption
7. Addressable Market
8. Key Points


HIT·IQ

Capital Structure

Capital Structure (21 July 2023)

ASX Code	HIQ
Share Price	$0.024
Shares on Issue	266.8 M
Unlisted Option ($0.04, Exp Dec 23')	134.3 M
Market Capitalisation	$6.40 M
Cash in Bank (31 Mar 2023)	$2.04 M

Shareholders



Board of Directors

Otto Buttula	Mike Vegar	Aidan Clarke	Glenn Smith	Phil Carulli
Non-Executive Chairman	Managing Director	Non-Executive Director	Non-Executive Director	Non-Executive Director
▸ Extensive financial, investment, IT & biotech experience ▸ Executive Chairman of Rhythm (ASX: RHY) ▸ Co-Founder and CEO of IWL (ASX: IWL) ▸ Founder/former CEO of Investors Mutual ▸ Former Director of Imugene (ASX:IMU) & Chairman of Investor First (ASX: HUB) ▸ Chairman of Oncosil Medical (ASX: OSL)	▸ Co-Founder of HIQ and led company since inception ▸ Extensive experience across elite sports (AIS) ▸ Co-Founded Australian leading mouthguard manufacturing business	▸ Co-Founder of 2XU ▸ Sales & Marketing Director leading 2XU to $100m revenue line ▸ Vast sales distribution networks globally, particularly in USA ▸ Founder of SA1NT Group	▸ Multi-decade career in technology commercialisation, international expansion & Health technology. ▸ Co-Founder & Investment Director of Aruma Capital ($50m VC Fund) ▸ Chairman & Investor at HealthcareLink ▸ Former Director of StartupAUS (now Tech Council) & GM Resonance Health (ASX:RHT)	▸ Chartered Accountant & Managing Director of Optima Partners ▸ HIQ non-executive director & CFO since August 2018 ▸ Non-Executive Director of Soar-Earth Limited ▸ Experienced investor, capital raising, corporate compliance & governance

Supported by World-Leading Advisors

Scientific & Medical Advisory Council (SMAC)



Honorary Associate Professor
Andrew Gardner
University of Newcastle, AUS

- Research Fellow, School of Medicine and Public Health, College of Health, Medicine, and Wellbeing, The University of Newcastle
- Clinical Neuropsychologist, Hunter New England Local Health District, Newcastle



Professor
Carolyn Emery
University of Calgary, CAN

- Professor, Faculty of Kinesiology, Canadian Institutes of Health Research Canada Research Chair (Tier 1) Concussion
- Chair, Sports Injury Prevention Research Centre, University of Calgary



Emeritus Professor
Jeffrey V. Rosenfeld AC OBE
Monash University, AUS

- Experienced senior neurosurgeon at Alfred Hospital, Melbourne
- Emeritus professor of surgery at Monash University, Melbourne



Doctor
Robby Sikka
USA

- New York Yankees Team Physician
- CEO of Sports Medicine Analytics Research Team (SMART)



Assistant Professor
Doug Terry
Vanderbilt University, USA

- Neuropsychologist at Vanderbilt University Medical Center in Nashville, TN, USA
- Director of the Center for Cognitive Neurosurgical Studies at Vanderbilt University in Nashville, TN.



Doctor
Joshua Goldman
UCLA, USA

- Assistant Clinical Professor, Departments of Family Medicine and Orthopaedic Surgery, UCLA

About

We are the global leader in concussion & brain health technologies in sport.


Our mission is to prioritise & preserve the brain health of athletes.

We will eliminate the risk of undetected and unmanaged head impacts through data driven solutions.



The Challenge - What is CTE?

There is emerging evidence of a link between head impact exposure and Chronic Traumatic Encephalopathy (CTE), a degenerative brain disease.



The largest study on CTE in American Football players estimates that for every 1,000 head impacts **CTE risk increases by ~20%.**

HIT•IQ technologies provide the solution for collecting accurate data to **measure, manage, and mitigate** head impacts.

HIT·IQ

Global Trends and Increased Concussion Awareness

An Australian Senate inquiry into concussion and repeat head trauma in contact sports has been conducted.

- ✓ Chief Medical Officers from major sports codes have now acknowledged the link between chronic head impact exposure and CTE/Neurodegenerative diseases.
- ✓ Senate inquiry findings due in August are likely to accelerate the adoption of technologies across codes and consumer pathways.
- ✓ Litany of legal cases emerging.



Australian Government

HIT·IQ

Nexus

The Nexus Instrumented Mouthguard accurately captures the frequency and intensity of head impacts.

15,000 datapoints per second.

Bluetooth enabled, near-real time data transfer with wireless charging & six-hour battery life.

Integrated world-class hardware & software solution.



Laboratory Testing

98% Accuracy

On-field Classification Performance

98% Sensitivity

93% Specificity

HIT·IQ

ConneQt

An integrated solution linking team managers, players, guardians and specialised physicians - delivering accessible concussion care.

- Digital Incident Reports
- Automated Alerts
- 24-hour Telehealth Access
- Comprehensive Analytics

The **highest standard** of sport-related concussion care.



HIT·IQ

CoVR

Assessing cognitive performance with VR (Virtual Reality).

Traditional pen and paper or iPad-based testing used for baseline or post injury assessments lack specificity and are prone to malingering.

- Comprehensive, Multi-modal Assessment
- Immersive, Gamified Experience
- Increased Sensitivity

Pre-clinical testing underway: 500 participants tested across normative and concussed cohorts from pre-clinical testing sites.



HIT·IQ

Global Data Collection

The largest global databank of head impacts and concussion assessments captured over 7 years.



- **40k** Athletes Monitored
- **490k+** Impacts Captured
- **130k+** Cognitive Assessments
- Player Head Impact Passports
- Third Party Risk Model Development
- Informing OH&S Policy

HIT·IQ

Strategies for Accelerating Adoption

Data from partnerships providing a gateway to both elite & consumer markets, underpinning our commercial strategy.

North America Elite

Partnership with
12 x NCAA D1 Football Programs

Partnerships have delivered:

- ✓ **70,000** impacts captured and foundational data set established.
- ✓ Demonstrated technology fit in target market.

North America Consumer

Collaboration with
Shock Doctor, Inc

World leading consumer mouthguard manufacturer:

- ✓ Unparalleled manufacturing and distribution network, with access to over **20,000** global retail outlets.
- ✓ Final stages of a co-developed over-the-counter instrumented mouthguard underway.

Addressable Markets

Significant global opportunity across multiple segments including elite, consumer and allied health.

	Teams/ Accounts	Athletes	**Nexus**	**ConneQt/CSX**	**CoVR**
Elite Sport	10k	500k	**$310m**	**$28m**	**$100m**
Consumer	110k	11m	**$3.6Bn**	**$77m**	
Allied Health	300k			**$1.5Bn**	**$3Bn**
Addressable Market			**$3.91Bn**	**$1.61Bn**	**$3.1Bn**

HIT•IQ Technology Adopted by:

- ✓ Military
- ✓ Australian Rules Football
- ✓ Rugby Union, League
- ✓ American Football
- ✓ Soccer, Cricket, Lacrosse
- ✓ MMA, Boxing

HIT·IQ

Key Points

- Link between CTE and repeat head impact exposure can’t be ignored.
- Escalating need for sporting codes to invest in objective, data led technology solutions to meet duty of care obligations.
- Unmet needs across $8B addressable market.
- Global leadership position in data driven solutions to prioritise and preserve brain health.
- Foundations built in key target markets.

HIT·IQ